Tirzepatide 15mg
Tirzepatide is a revolutionary dual GIP/GLP-1 receptor agonist FDA-approved for both type 2 diabetes and chronic weight management. It's one of the most potent weight loss compounds available.
MECHANISM OF ACTION
Tirzepatide mimics two incretin hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual action simultaneously reduces appetite through hypothalamic signaling, slows gastric emptying, improves insulin sensitivity, and suppresses glucagon. The dual mechanism is significantly more effective than single GLP-1 agonists like Semaglutide.
POTENTIAL BENEFITS
Dramatic weight loss: 15-22% body weight reduction
Superior blood sugar control and insulin sensitivity
Reduced cardiovascular risk (26% reduction in major adverse events)
Appetite suppression without central nervous system stimulation
Preserved muscle mass during weight loss
Improved metabolic health markers
WHY IT'S BEING RESEARCHED
Tirzepatide addresses a critical limitation of single-mechanism GLP-1 drugs. By targeting both GIP and GLP-1 pathways, it achieves superior metabolic effects with a once-weekly injection, making it more convenient and effective than daily alternatives.
INTERESTING FACTS
39 amino acids with a C20 fatty acid conjugation enabling once-weekly dosing
Outperforms Semaglutide in head-to-head trials for weight loss
Appetite reduction occurs within 1-3 days of first injection
Full metabolic benefits require 12-24+ weeks minimum
CRITICAL SAFETY NOTES
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
Monitor for acute pancreatitis (severe abdominal pain radiating to back)
Avoid combining with other GLP-1 agonists (Semaglutide, liraglutide) — increases hypoglycemia and GI side effects
May require significant insulin dose reduction
Synergistic with metformin for enhanced diabetes control
Compatible with CJC-1295 to preserve muscle during rapid weight loss
RESEARCH PURPOSES ONLY
NOT AVAILABLE FOR HUMAN CONSUMPTION
